gap junction protein gamma 3Genealiases: CX29 · CX30.2 · CX31.3 · GJE1
Q-omics provides the consensus-scored GJC3 profile across patient tissues and cancer cell-line models. GJC3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GJC3 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, GJC3 RNA expression shows 15,766 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRP, and THYM as cancer lineages where GJC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GJC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GJC3 survival associations across molecular data types. GJC3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GJC3 RNA expression–survival associations across cancer types. High GJC3 expression shows unfavorable associations in MESO, but favorable associations in UVM, KIRP, KIRC, LAML and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GJC3 RNA expression.
This table summarizes GJC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GJC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GJC3 shows lower tumor expression in KIRP, KIRC, UCEC, BRCA and HNSC and higher tumor expression in COAD. The KIRP box plot shows higher GJC3 RNA expression in normal versus tumor tissue (log2 FC = −0.612, t-test p < 0.001).
This table shows molecular features associated with GJC3 in patient tissues and cancer cell lines. In patient samples, GJC3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GJC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
